A Phase 1 interventional study of TD-1473 oral capsule and [14C]-TD-1473 IV bolus in Intestinal Disorders and Bowel Diseases, Inflammatory, sponsored by Theravance Biopharma. Completed at 1 site in United States. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-14.
Sponsored by Theravance Biopharma (part of Zymeworks) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 244th largest by enrollment of the 327 interventional ones that give a count, is one of 24 that started in 2018, is one of 44 in phase 1, and was the 232nd registered.
1,552 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.
Browse Inflammatory Bowel Diseases studies →103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Palisade Bio · Sites in United States, Canada, Czechia and 9 more countries
Ages 18–75
Eli Lilly and Company · Sites in United States, Canada, Denmark and 4 more countries
Ages 3 wk+ · Women only
University of Michigan · Sites in United States
Ages 18+
Hope Biosciences Research Foundation · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 275 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 115 (42%) stop at 75 or younger; 76 take children under 18; 60 take healthy volunteers.
This study: 19 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
463 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 59 · Phase 2 83 · Phase 3 46 · Phase 4 31
First in 1995; this study’s year is marked. 24 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 68 across 872 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 50 across the 327 interventional studies, 134 across the 132 observational. Of the 301 that completed or were terminated, 120 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
132 of 463 have an industry lead sponsor. The 10 most frequent:
This study is registered under Theravance Biopharma, one of the names counted as Zymeworks. Under that name alone:
Theravance Biopharma is the lead sponsor of 47 studies on the registry; none are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
Zymeworks has 7 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
42 of the studies in Inflammatory Bowel Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT04508088Massachusetts General HospitalSkeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease | 2026-12 |
| NCT07769437University Hospitals Cleveland Medical CenterNon-nutritive Sweeteners in Inflammatory Bowel Disease | 2026-12 |
| NCT06065228Children's National Research InstituteTherapeutic Endpoint in Pediatric IBD Conditions | 2026-12 |
Add all 42 to your calendar (.ics) → With an account.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, 2-cohort study to evaluate the absolute bioavailability, absorption, distribution, metabolism and excretion of TD-1473 in healthy male subjects. Subjects in cohort 1 will receive a single oral dose of TD-1473 and a single intravenous bolus dose of [14C]-TD-1473. Subjects in cohort 2 will receive a single oral dose of [14C]-TD-1473 only.
1,552 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.
This study's enrollment of 20 is below the median of 68 across 872 interventional studies indexed under Inflammatory Bowel Diseases.
Browse Inflammatory Bowel Diseases studies →Theravance Biopharma is the lead sponsor of 47 studies on the registry; none are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
First submitted before Theravance Biopharma became part of Zymeworks.
Compared within Inflammatory Bowel Diseases, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Intestinal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 - One oral dose and IV bolus administered 1 hr after oral dose of TD-1473
Drug: TD-1473 oral capsule · Drug: [14C]-TD-1473 IV bolus
Cohort 2 - One oral dose
Drug: [14C]-TD-1473 Oral Capsule
(Intervention description included in arm description)
(Intervention description included in arm description)
(Intervention description included in arm description)
Maximum observed concentration (Cmax) in Plasma
Time frame: Up to 15 days
Time to maximum observed concentration (tmax) in Plasma
Time frame: Up to 15 days
Area under the concentration-time curve from hour 0 to the last measurable concentration (AUC0-last) in Plasma
Time frame: Up to 15 days
Area under the concentration-time curve extrapolated to infinity (AUC0-inf) in Plasma
Time frame: Up to 15 days
Apparent terminal elimination half-life (t1/2) in Plasma
Time frame: Up to 15 days
Apparent clearance (Cl/F) in Plasma
Time frame: Up to 15 days
Apparent volume of distribution (Vz/F) in Plasma
Time frame: Up to 15 days
Absolute bioavailability (%F) in Plasma
Time frame: Up to 15 days
Amount excreted in urine (Aeu) over the sampling interval in Urine
Time frame: Up to 15 days
Renal clearance (CLr) in Urine
Time frame: Up to 15 days
The percent excreted in urine (%Feu) in Urine
Time frame: Up to 15 days
Amount excreted in feces (Aef) over the sampling interval in Feces
Time frame: Up to 15 days
The percent excreted in feces (%Fef)
Time frame: Up to 15 days
Metabolites in Plasma
TD 1473 metabolite profiling will be performed in plasma containing sufficient amounts of radioactivity
Time frame: Up to 15 days
Metabolites in Urine
TD 1473 metabolite profiling will be performed in urine containing sufficient amounts of radioactivity
Time frame: Up to 15 days
Metabolites in Feces
TD-1473 metabolite profiling will be performed in feces containing sufficient amounts of radioactivity
Time frame: Up to 15 days
Plan to share: No — Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.
No publications or documents are linked to this record.
Ran from Jan 2018 to primary completion in Feb 2018, 0 months.
Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 0 months is below that.
Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Izencitinib